PPARβ/δ agonists mimicked obesity effects and inhibited trafficking of the cytotoxic machinery to the NK cell-tumor junction, disenabling NK cells to reduce tumor growth in obesity in vivo. The gene discussed is PPARD; the disease is neoplasm.